Stéphane LOLIGNIER (EN)
UMR 1107 INSERM/UCA Neuro-Dol
Facultés de Médecine et Pharmacie
Place Henri Dunant
63001 Clermont-Ferrand
FRANCE
Dr. Stéphane LOLIGNIER
Assistant Professor
Fundamental Pharmacology and Pain Clinic Team, TEAM 2 – Molecular and Cellular Pain Modulators Axis
Stephane.LOLIGNIER@-Code to remove to avoid SPAM-uca.fr
+33 4 73 17 82 35
Student :
Research Theme:
My research focuses on the understanding of the molecular mechanisms underlying different modalities of somatosensation such as pain, itch and touch. I study the role of receptors and ion channels in the transduction, transmission and modulation of sensory information using different experimental approaches (electrophysiology, imaging, behavior and machine learning). In parallel, I work on the development of new analgesic drug candidates using high-throughput screening and in collaboration with chemists. To this aim, I now focus on the pharmacological potential of venom toxins.
Functions:
Junior member of Institut Universitaire de France (chaire Innovation 2024-2029)
Teachings:
I teach neurosciences and pharmacology in B.Sc. and M.Sc. programs. I am responsible for the neuropsychopharmacology training in the Drug Sciences Master program. I regularly train interns and supervise Ph.D. students (cf. CV).
Additional Information:
CV:
HAL Publications
Journal articles
2021
- ref_biblio
- Vanessa Pereira, Sylvain Lamoine, Mélissa Cuménal, Stéphane Lolignier, Youssef Aissouni, et al.. Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity. Molecular Neurobiology, 2021, 58 (7), pp.3575-3587. ⟨10.1007/s12035-021-02361-6⟩. ⟨hal-03511787⟩
- Accès au bibtex
-
2020
- ref_biblio
- Jérôme Busserolles, Ismail Ben Soussia, Laetitia Pouchol, Nicolas Marie, Mathieu Meleine, et al.. TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects. British Journal of Pharmacology, 2020, 177 (20), pp.4782-4795. ⟨10.1111/bph.15243⟩. ⟨hal-03512213⟩
- Accès au texte intégral et bibtex
-
- ref_biblio
- Jérôme Busserolles, Stéphane Lolignier, Nicolas Kerckhove, Célian Bertin, Nicolas Authier, et al.. Replacement of current opioid drugs focusing on MOR-related strategies. Pharmacology and Therapeutics, 2020, 210, pp.107519. ⟨10.1016/j.pharmthera.2020.107519⟩. ⟨hal-03490336⟩
- Accès au texte intégral et bibtex
-
- ref_biblio
- Dimitra Gkika, Stéphane Lolignier, Guillaume Grolez, Alexis Bavencoffe, Georges Shapovalov, et al.. Testosterone‐androgen receptor: The steroid link inhibiting TRPM8‐mediated cold sensitivity. FASEB Journal, 2020, 34 (6), pp.7483-7499. ⟨10.1096/fj.201902270R⟩. ⟨hal-03512394⟩
- Accès au texte intégral et bibtex
-
2018
- ref_biblio
- Alexandros H Kanellopoulos, Jennifer Koenig, Honglei Huang, Martina Pyrski, Queensta Millet, et al.. Mapping protein interactions of sodium channel Na V 1.7 using epitope‐tagged gene‐targeted mice. EMBO Journal, 2018, 37 (3), pp.427 – 445. ⟨10.15252/embj.201796692⟩. ⟨hal-03512558⟩
- Accès au texte intégral et bibtex
-
- ref_biblio
- Yao Potchoo, Edem Goeh-Akue, Findibe Damorou, Stéphane Lolignier, Barima Massoka, et al.. Antihypertensive Drug Regimen for High Blood Pressure Associated with Modifiable Cardiovascular Risk Factors Among Hypertensive Patients Attending Campus Teaching Hospital of Lomé, Togo, West Africa. Journal of Pharmaceutical and Pharmacological Sciences, 2018, 3 (1), pp.1-9. ⟨10.29011/2574-7711⟩. ⟨hal-03111109⟩
- Accès au texte intégral et bibtex
-
- ref_biblio
- Laura Poupon, Sylvain Lamoine, Vanessa Pereira, David Barriere, Stéphane Lolignier, et al.. Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology, 2018, 140, pp.43-61. ⟨10.1016/j.neuropharm.2018.07.026⟩. ⟨hal-02065469⟩
- Accès au texte intégral et bibtex
-
- ref_biblio
- Ramin Raouf, Stéphane Lolignier, Jane Sexton, Queensta Millet, Sonia Santana-Varela, et al.. Inhibition of somatosensory mechanotransduction by annexin A6. Science Signaling, 2018, 11 (535), ⟨10.1126/scisignal.aao2060⟩. ⟨hal-03512530⟩
- Accès au bibtex
-
2017
- ref_biblio
- Delphine Vivier, Ismail Ben Soussia, Nuno Rodrigues, Stéphane Lolignier, Maïly Devilliers, et al.. Development of the First Two-Pore Domain Potassium Channel TWIK-Related K + Channel 1-Selective Agonist Possessing in Vivo Antinociceptive Activity. Journal of Medicinal Chemistry, 2017, 60 (3), pp.1076-1088. ⟨10.1021/acs.jmedchem.6b01285⟩. ⟨hal-02390407⟩
- Accès au bibtex
-
2016
- ref_biblio
- Stéphane Lolignier, Dimitra Gkika, David Andersson, Enrico Leipold, Irina Vetter, et al.. New Insight in Cold Pain: Role of Ion Channels, Modulation, and Clinical Perspectives. Journal of Neuroscience, 2016, 36 (45), pp.11435 – 11439. ⟨10.1523/jneurosci.2327-16.2016⟩. ⟨hal-03512571⟩
- Accès au texte intégral et bibtex
-
- ref_biblio
- Stéphane Lolignier, Alain Eschalier, Caroline Bonnet, Patrick Delmas, Jérôme Busserolles. Le canal Nav1.9 : protéine clé pour la perception du froid et cible thérapeutique potentielle contre la douleur. Médecine/Sciences, 2016, 32 (2), pp.162 – 165. ⟨10.1051/medsci/20163202009⟩. ⟨hal-01795185⟩
- Accès au texte intégral et bibtex
-
2015
- ref_biblio
- Jennifer Koenig, Robert Werdehausen, John E Linley, Abdella M Habib, Jeffrey Vernon, et al.. Regulation of Na v 1.7: A Conserved SCN9A Natural Antisense Transcript Expressed in Dorsal Root Ganglia. PLoS ONE, 2015, 10 (6), pp.e0128830. ⟨10.1371/journal.pone.0128830⟩. ⟨hal-03512591⟩
- Accès au texte intégral et bibtex
-
- ref_biblio
- Stéphane Lolignier, Caroline Bonnet, Christelle Gaudioso, Jacques Noël, Jérôme Ruel, et al.. The Nav1.9 Channel Is a Key Determinant of Cold Pain Sensation and Cold Allodynia. Cell Reports, 2015, ⟨10.1016/j.celrep.2015.04.027⟩. ⟨hal-01208540⟩
- Accès au texte intégral et bibtex
-
- ref_biblio
- Michael S Minett, Vanessa Pereira, Shafaq Sikandar, Ayako Matsuyama, Stéphane Lolignier, et al.. Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7. Nature Communications, 2015, 6, pp.8967. ⟨10.1038/ncomms9967⟩. ⟨hal-03512580⟩
- Accès au texte intégral et bibtex
-
2014
- ref_biblio
- Stéphane Lolignier, Niels Eijkelkamp, John N Wood. Mechanical allodynia. Pflügers Archiv European Journal of Physiology, 2014, 467 (1), pp.133 – 139. ⟨10.1007/s00424-014-1532-0⟩. ⟨hal-03512600⟩
- Accès au texte intégral et bibtex
-
- ref_biblio
- Kathryn Paterson, Stéphane Lolignier, John N Wood, Stephen B Mcmahon, David L H Bennett. Botulinum Toxin-A Treatment Reduces Human Mechanical Pain Sensitivity and Mechanotransduction. Annals of Neurology, 2014, 75 (4), pp.591-596. ⟨10.1002/ana⟩. ⟨hal-03512611⟩
- Accès au bibtex
-
2013
- ref_biblio
- Maïly Devilliers, Jérôme Busserolles, Stéphane Lolignier, Emmanuel Deval, Vanessa Pereira, et al.. Activation of TREK-1 by morphine results in analgesia without adverse side effects. Nature Communications, 2013, 4, ⟨10.1038/ncomms3941⟩. ⟨hal-01689367⟩
- Accès au texte intégral et bibtex
-
2011
- ref_biblio
- Stéphane Lolignier, Muriel Amsalem, François Maingret, Françoise Padilla, Mélanie Gabriac, et al.. Nav1.9 Channel Contributes to Mechanical and Heat Pain Hypersensitivity Induced by Subacute and Chronic Inflammation. PLoS ONE, 2011, 6 (8), pp.23083. ⟨10.1371/journal.pone.0023083⟩. ⟨hal-01689907⟩
- Accès au texte intégral et bibtex
-
2008
- ref_biblio
- Carine Chassain, Guy Bielicki, Elodie Durand, Stéphane Lolignier, Fatma Essafi, et al.. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson’s disease, the MPTP-intoxicated mouse. Journal of Neurochemistry, 2008, 105 (3), pp.874-882. ⟨10.1111/j.1471-4159.2007.05185.x⟩. ⟨hal-01602181⟩
- Accès au bibtex
-
Theses
2011
- ref_biblio
- Stéphane Lolignier. Rôle du canal sodique Nav1.9 dans la douleur inflammatoire, dans la perception du froid et dans l’hypersensibilité au froid induite par l’oxaliplatine. Médecine humaine et pathologie. Université d’Auvergne – Clermont-Ferrand I, 2011. Français. ⟨NNT : 2011CLF1MM28⟩. ⟨tel-00855512⟩
- Accès au texte intégral et bibtex
-